Literature DB >> 1418854

AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes.

K H Leung1, R S Chang, V J Lotti, W A Roscoe, R D Smith, P B Timmermans, A T Chiu.   

Abstract

Angiotensin II (AII) can release arachidonic acid metabolites such as prostacyclin (PGI2) and PGE2 from cells in cultures. It has recently been reported that the AT1 selective nonpeptide AII receptor antagonist losartan had similar effects. The present study was undertaken to further evaluate the effects of AII and losartan on cells which synthesize prostaglandins, including vascular smooth muscle, endothelial, and glial cells. Inhibition of specific [125I]AII binding was demonstrated in porcine smooth muscle cell (PSMC) suspensions with unlabeled AII and losartan. The IC50 values were 1.3 x 10(-9) mol/L and 7.7 x 10(-9) mol/L, respectively. PD123177 (an AT2 selective antagonist) had no effect on binding. AII produced a concentration-related increase in calcium mobilization (fura-2 fluorescence) which was blocked by losartan (IC50 = 8.4 x 10(-8) mol/L) but not by PD123177 (10(-6) mol/L). AII (10(-7) to 10(-5) mol/L) stimulated the basal release of PGI2 by 100%. This response was blocked by losartan (10(-6) to 10(-5) mol/L) but not by PD123177 (10(-6) to 10(-5) mol/L) and neither agent stimulated basal release in PSMC. Similar effects of AII and antagonists were observed upon receptor binding and PGE2 release in primary rat astrocyte (RA) cultures. AII did not release PGI2 from porcine endothelial cells, bovine pulmonary arterial endothelial cells, or rat C6 glioma cells. Losartan had no significant effect at 10(-5) mol/L. By contrast, bradykinin or the calcium ionophore A23187 dramatically increased PGI2 release in each of these cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418854     DOI: 10.1093/ajh/5.9.648

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain.

Authors:  Xian Cao; Jeffrey R Peterson; Gang Wang; Josef Anrather; Colin N Young; Mallikarjuna R Guruju; Melissa A Burmeister; Costantino Iadecola; Robin L Davisson
Journal:  Hypertension       Date:  2012-02-27       Impact factor: 10.190

3.  COX-1-derived PGE2 and PGE2 type 1 receptors are vital for angiotensin II-induced formation of reactive oxygen species and Ca(2+) influx in the subfornical organ.

Authors:  Gang Wang; Pallabi Sarkar; Jeffrey R Peterson; Josef Anrather; Joseph P Pierce; Jamie M Moore; Ji Feng; Ping Zhou; Teresa A Milner; Virginia M Pickel; Costantino Iadecola; Robin L Davisson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-06       Impact factor: 4.733

4.  Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor.

Authors:  H M Siragy; T Senbonmatsu; T Ichiki; T Inagami; R M Carey
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

5.  Vascular smooth-muscle cells contain AT1 angiotensin receptors coupled to phospholipase D activation.

Authors:  E J Freeman; E A Tallant
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

6.  Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart.

Authors:  I Pörsti; M Hecker; E Bassenge; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

7.  AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma.

Authors:  E Rivera; O Arrieta; P Guevara; A Duarte-Rojo; J Sotelo
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.